Age-related Macular Degeneration Pipeline Analysis 2018 - Focusing On Clinical Trials And Results, Drug Profiling, Patents, Collaborations, And Other Developments

  • Published : Mar 2020
  • Report Code : KSI061612846
  • Pages : 94

Age-related Macular Degeneration Pipeline Analysis report covers approximately 45 drugs currently in different phases of development. Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving and happens when a part of the retina called the macula is damaged. As AMD progresses, a blurred area near the center of vision is a common symptom. Over time, the blurred area may grow larger or you may develop blank spots in your central vision. Objects also may not appear to be as bright as they used to be.

The report provides Age-related Macular Degeneration treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Alcon, Hoffmann-La Roche. and Regenxbio Inc. among others.


By Company

By Phase

By Molecule Type

By Region

By Route of Administration

1. Introduction

1.1. Research Methodology

1.2. Research Scope

1.2.1. Analysis by Company

1.2.2. Analysis by Phase

1.2.3. By Molecule Type

1.2.4. By region

2. Disease Overview

2.1.1. Introduction

2.1.2. Classification

2.1.3. Symptoms

2.1.4. Causes

2.1.5. Diagnoses

2.1.6. Treatment

2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

5.2.1. Phase of Development Introduction Drug Profiling

• Drug Name

• Generic Name

• Synonyms

• Company

• Collaborator

• Route of administration

• Target

• Mechanism of Action

• Technology

• Molecule type

• CAS Number

• Weight

• Chemical Formula

• IUPAC name

• ATC code Strategic Developments Clinical trials Clinical trial results Patents Technology

5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)

5.3. By Molecule type

5.4. Analysis by Region

6. Company profiling

6.1. Alcon

6.1.1. Introduction

6.1.2. Financials

6.1.3. Products and Services

6.1.4. Recent Developments

6.1.5. SWOT

6.2. Astellas Pharma Inc

6.2.1. Introduction

6.2.2. Financials

6.2.3. Products and Services

6.2.4. Recent Developments

6.2.5. SWOT

6.3. RegenXBio Inc.

6.3.1. Introduction

6.3.2. Financials

6.3.3. Products and Services

6.3.4. Recent Developments

6.3.5. SWOT

6.4. Hoffmann-La Roche

6.4.1. Introduction

6.4.2. Financials

6.4.3. Products and Services

6.4.4. Recent Developments

6.4.5. SWOT

6.5. Alkahest, Inc.

6.5.1. Introduction

6.5.2. Financials

6.5.3. Products and Services

6.5.4. Recent Developments

6.5.5. SWOT

6.6. Allergan

6.6.1. Introduction

6.6.2. Financials

6.6.3. Products and Services

6.6.4. Recent Developments

6.6.5. SWOT

6.7. Opthea

6.7.1. Introduction

6.7.2. Financials

6.7.3. Products and Services

6.7.4. Recent Developments

6.7.5. SWOT

6.8. Belite Bio

6.8.1. Introduction

6.8.2. Financials

6.8.3. Products and Services

6.8.4. Recent Developments

6.8.5. SWOT

6.9. SciFluor Life Sciences, Inc.

6.9.1. Introduction

6.9.2. Financials

6.9.3. Products and Services

6.9.4. Recent Developments

6.9.5. SWOT

6.10. Biophytis

6.10.1. Introduction

6.10.2. Financials

6.10.3. Products and Services

6.10.4. Recent Developments

6.10.5. SWOT

List of Tables

List of Figures


Astellas Pharma Inc

RegenXBio Inc.

Hoffmann-La Roche

Alkahest, Inc.



Belite Bio

SciFluor Life Sciences, Inc.